ACADIA Pharmaceuticals (ACAD) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) recently:

  • 2/7/2017 – ACADIA Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $44.00 price target on the stock.
  • 2/6/2017 – ACADIA Pharmaceuticals was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $41.20 price target on the stock.
  • 2/2/2017 – ACADIA Pharmaceuticals is now covered by analysts at Ladenburg Thalmann Financial Services. They set a “buy” rating and a $48.00 price target on the stock.
  • 1/31/2017 – ACADIA Pharmaceuticals was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $37.64 price target on the stock.
  • 1/24/2017 – ACADIA Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $42.00 price target on the stock.
  • 1/24/2017 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $49.00 price target on the stock.
  • 1/14/2017 – ACADIA Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $42.00 price target on the stock.
  • 1/11/2017 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 1/11/2017 – ACADIA Pharmaceuticals was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $35.23 price target on the stock.
  • 1/10/2017 – ACADIA Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “
  • 1/2/2017 – ACADIA Pharmaceuticals was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $35.18 price target on the stock.
  • 12/28/2016 – ACADIA Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock.
  • 12/26/2016 – ACADIA Pharmaceuticals was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $31.50 price target on the stock.
  • 12/23/2016 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $49.00 price target on the stock.
  • 12/23/2016 – ACADIA Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $44.00 price target on the stock.
  • 12/23/2016 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
  • 12/21/2016 – ACADIA Pharmaceuticals had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $49.00 price target on the stock.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded up 0.40% during mid-day trading on Monday, hitting $37.24. 1,925,030 shares of the stock traded hands. The company’s market cap is $4.51 billion. The company’s 50 day moving average is $32.47 and its 200 day moving average is $30.35. ACADIA Pharmaceuticals Inc. has a 12 month low of $17.02 and a 12 month high of $42.49.

In other news, EVP Glenn Baity sold 9,800 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, December 27th. The stock was sold at an average price of $30.46, for a total transaction of $298,508.00. Following the transaction, the executive vice president now owns 81,363 shares in the company, valued at approximately $2,478,316.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.65% of the stock is owned by insiders.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

5 Day Chart for NASDAQ:ACAD

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/acadia-pharmaceuticals-acad-investment-analysts-weekly-ratings-changes/1658720.html

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *